Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Alnuctamab + Mezigdomide in Relapsed and/or Refractory Multiple Myeloma
2023-504367-16-00Phase 2Withdrawn
- Sponsor
- Celgene Corporation
- Start
- Jan 2024
- Modality
- T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Molecular Glues → Targeted Protein Degraders (TPDs) → Small Molecules
- Countries
- 3
01
Overview
Phase 2, open-label trial of alnuctamab and mezigdomide in multiple myeloma (MM) (3 arms), sponsored by Celgene Corporation. Primary endpoints: Safety: type, frequency, seriousness, and severity of all adverse events, Recommended Phase 2 dose (RP2D) and dosing schedule of mezigdomide in combination with alnuctamab and 1 more. Planned start Jan 2024; status: withdrawn.
02
Drugs
alnuctamabmezigdomide
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on 2023-504367-16-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-504367-16-00.